PET scanning and measuring the impact of treatment

被引：20

作者：

Cohade, C ^{[1
]}

Wahl, RL ^{[1
]}

机构：

[1] Johns Hopkins Univ Hosp, Div Nucl Med, Russel H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA

来源：

CANCER JOURNAL | 2002年 / 8卷 / 02期

关键词：

PET; FDG; fluorodeoxyglucose; cancer; response; therapy; radionuclide imaging; positron emission tomography;

D O I：

10.1097/00130404-200203000-00006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Positron emission tomography (PET) scanning with F18-fluorode-oxyglucose or FDG is a becoming a standard method for tumor staging. The prediction and evaluation of therapy response are newer applications of FDG-PET, PET often offers an early read-out of treatment efficacy and is an attractive alternative to conventional anatomic assessments of treatment response. This article reviews the methods available with PET to monitor therapy response. Disease specific applications of PET imaging are then reviewed. While FDG is the most commonly used radiotracer for PET, many other radioligands could be applied in the future.

引用

页码：119 / 134

页数：16

共 114 条

[71]

NAGATA Y, 1990, J COMPUT ASSIST TOMO, V14, P370

[72]

Nair, 2000, Clin Positron Imaging, V3, P79, DOI 10.1016/S1095-0397(00)00037-6

[73] Clinical value of positron emission tomography with FDG for recurrent ovarian cancer [J].